Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,264 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pathways Clear all
Recruiting Not applicable Interventional

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

NCT07214532
View directory record Official record
Conditions
Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Interventions
ctDNA-Guided Treatment Strategy
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
49
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Active, not recruiting Phase 2 Interventional

Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients

NCT05637216
View directory record Official record
Conditions
Radiation Induced Fibrosis
Interventions
Losartan 25 milligram capsule, Placebo
Drug
Lead sponsor
Shaw Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Edwards, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Terminated Phase 1 Interventional

SU5416 in Treating Children With Recurrent or Progressive Brain Tumors

NCT00006247
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
semaxanib
Drug
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
Up to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
9
States / cities
San Francisco, California • Washington D.C., District of Columbia • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Not applicable Interventional

Investigating Targetable Metabolic Pathways Sustaining Pancreatic Cancer

NCT05296421
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
Biopsy, Therapeutic Conventional Surgery, Uniformly-labeled [13C]glucose
Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Livingston, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Terminated Phase 1 Interventional

Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors

NCT07121829
View directory record Official record
Conditions
Melanoma, Solid Tumor, Pilocytic Astrocytoma, Non Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, MAP Kinase Family Gene Mutation, RAS Mutation, RAF Mutation, MEK Mutation
Interventions
Tovorafenib, Tovorafenib Drug: Pimasertib
Drug
Lead sponsor
Day One Biopharmaceuticals, Inc.
Industry
Eligibility
12 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Newport Beach, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Implementing Pathways to Improve Pediatric Asthma Care

NCT03736603
View directory record Official record
Conditions
Asthma
Interventions
PIPA Intervention Bundle 1, PIPA Intervention Bundle 2
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2022 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment

NCT02927769
View directory record Official record
Conditions
Hodgkin Disease
Interventions
Nivolumab, brentuximab vedotin, bendamustine
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 30 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 2 Interventional

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

NCT07223541
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting No phase listed Observational

Study of Normal Intestinal Development and Disease in Premature and Term Neonates

NCT06681129
View directory record Official record
Conditions
NEC, Necrotizing Enterocolitis, Intestinal Disease, Human Development
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 2 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Solving Stigma Through POV Simulation: Enhancing Pharmacist Empathy-based Practices With Sickle Cell Disease Patients

NCT07217548
View directory record Official record
Conditions
Stigma
Interventions
point of view simulation, Control
Behavioral
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Testing Glial Pathways to HAAF in Human Subjects Using Carbon 13 Magnetic Resonance Spectroscopy

NCT02690168
View directory record Official record
Conditions
Diabetes Complications, Hypoglycemia
Interventions
Fasting
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 40 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Not applicable Interventional

Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy

NCT07225205
View directory record Official record
Conditions
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
Interventions
Intravenous fluids, ERAS
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sleep, Dreaming, and Virtual Reality for Mental Health

NCT07408206
View directory record Official record
Conditions
Anxiety
Interventions
Dream Yoga Inspired Intervention, Sleep Health Enhancement Program (SHEP)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Evanston, Illinois • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma

NCT01339052
View directory record Official record
Conditions
Glioblastoma
Interventions
BKM120, Surgery
Drug · Procedure
Lead sponsor
L. Nicolas Gonzalez Castro, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adverse Adolescent Pathways to Substance Use

NCT06977178
View directory record Official record
Conditions
Anxiety, Adolescent Development, Substance Use
Interventions
Trier Social Stress Test
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 14 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 4 Interventional Results available

Development of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

NCT03233438
View directory record Official record
Conditions
Bacterial Infections, Acute Bacterial Skin and Skin Structure Infection
Interventions
Dalbavancin, Usual Care
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 16, 2026, 10:08 PM EDT
Active, not recruiting Not applicable Interventional

PICU Up!: A Pilot Stepped-wedge Trial of a Multicomponent Early Mobility Intervention for Critically Ill Children

NCT03860168
View directory record Official record
Conditions
Critical Illness
Interventions
PICU Up!
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 24 Years
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Recruiting Phase 1Phase 2 Interventional

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

NCT06253494
View directory record Official record
Conditions
Endometrial Cancer, Cancer of Endometrium, Carcinoma of Endometrium, Endometrial Carcinoma
Interventions
AdHER2DC vaccine, Pembrolizumab, N-803, Lenvatinib, PATHWAY HER2 (4B5) assay
Biological · Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway

NCT04200911
View directory record Official record
Conditions
Cognitive Impairment, Mild, Alzheimer Disease
Interventions
Rapamune
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
55 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 2 Interventional Results available

RO4929097 in Treating Patients With Metastatic Colorectal Cancer

NCT01116687
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
gamma-secretase/Notch signalling pathway inhibitor RO4929097, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 16, 2026, 10:08 PM EDT
Enrolling by invitation Phase 4 Interventional

Prospective Opioid-Free AIS Fusion

NCT06935331
View directory record Official record
Conditions
Adolescent Idiopathic Scoliosis (AIS)
Interventions
Opioid-Free/Opioid-Avoidant, Opioid-Containing
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
10 Years to 20 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 16, 2026, 10:08 PM EDT
Completed Phase 1 Interventional

Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neovascular Age-Related Macular Degeneration

NCT01033721
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Palomid 529
Drug
Lead sponsor
Paloma Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 16, 2026, 10:08 PM EDT
Withdrawn Phase 3 Interventional

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer

NCT03048136
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
San Francisco, California • Lincoln, Nebraska • Hackensack, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 16, 2026, 10:08 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Northwest Therapies Trauma Psilocybin Study Compassionate Use Study

NCT05042466
View directory record Official record
Conditions
Trauma, Nervous System
Interventions
Trauma
Drug
Lead sponsor
NWTraumatherapies
Network
Eligibility
21 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 16, 2026, 10:08 PM EDT